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Background: Human enterovirus 71 (EV71) is an important pathogen caused large outbreaks in Asian-Pacific region
with severe neurological complications and may lead to death in young children. Understanding of the etiological
spectrum and epidemic changes of enterovirus and population’s immunity against EV71 are crucial for the
implementation of future therapeutic and prophylactic intervention.
Results: A total of 1,182 patients who presented with the symptoms of hand foot and mouth disease (67.3%) or
herpangina (HA) (16.7%) and admitted to the hospitals during 2008-2013 were tested for enterovirus using
pan-enterovirus PCR targeting 5′-untranslated region and specific PCR for viral capsid protein 1 gene. Overall, 59.7%
were pan-enterovirus positive comprising 9.1% EV71 and 31.2% coxsackievirus species A (CV-A) including 70.5%
CV-A6, 27.6% CV-A16, 1.1% CV-A10, and 0.8% CV-A5. HFMD and HA occurred endemically during 2008-2011. The
number of cases increased dramatically in June 2012 with the percentage of the recently emerged CV-A6
significantly rose to 28.4%. Co-circulation between different EV71 genotypes was observed during the outbreak.
Total of 161 sera obtained from healthy individuals were tested for neutralizing antibodies (NAb) against EV71
subgenotype B5 (EV71-B5) using microneutralization assay. The seropositive rate of EV71-B5 was 65.8%. The
age-adjusted seroprevalence for individuals was found to be lowest in children aged >6 months to 2 years (42.5%).
The seropositive rate remained relatively low in preschool children aged > 2 years to 6 years (48.3%) and thereafter
increased sharply to more than 80% in individuals aged > 6 years.
Conclusions: This study describes longitudinal data reflecting changing patterns of enterovirus prevalence over
6 years and demonstrates high seroprevalences of EV71-B5 NAb among Thai individuals. The rate of EV71
seropositive increased with age but without gender-specific significant difference. We identified that relative lower
EV71 seropositive rate in early 2012 may demonstrate widely presented of EV71-B5 in the population before
account for a large outbreak scale epidemic occurred in 2012 with due to a relatively high susceptibility of the
younger population.
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Human enterovirus 71 (EV71) is a group of genetically
diverse viruses belonging to the genus Enterovirus spe-
cies A, family Picornaviridae. EV71 was first isolated
from an infant with encephalitis in California in 1969,
but retrospective studies in the Netherlands using the
clinical specimens collected in 1963 [1] combined with
evolutionary analysis suggest that EV71 could have* Correspondence: yong.p@chula.ac.th
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article, unless otherwise stated.emerged as early as 1941 [2]. Since then, the virus has
spread worldwide and has been implicated as the pre-
dominant causative pathogen in the outbreaks of hand,
foot, and mouth disease (HFMD) and herpangina (HA).
Infection by EV71 is often asymptomatic, but may mani-
fest as self-limiting disease with mild flu-like symptoms.
However, in some cases, EV71 infection may cause
polio-like myelitis, brainstem encephalitis, aseptic men-
ingitis, and even death resulting from complications
[3-9]. Mortality rates due to EV71 infection in the
Asian-Pacific countries ranged from < 0.5% and up to
19% [10-14]. Although infection by other enterovirusesntral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ical manifestation as EV71, the symptoms are milder
with a much lower incidence of severe complications
[15-17]. Therefore, early and accurate detection of EV71
in clinical settings is considered a medical necessity.
EV71 is an icosahedral encapsulated particle, which
comprises a positive-sense single-stranded RNA genome of
approximately 7.4 kb in length. The linear genome is orga-
nized in a single long open reading frame (ORF) flanked by
the 5′ and short 3′-untranslated regions (UTR) with a poly-
adenylated tail. The ORF encodes a polyprotein which is
processed to form the four mature structural capsid pro-
teins (VP1-VP4) and seven non-structural proteins (2A-2C
and 3A-3D) responsible for viral replication and protein
processing. VP1 is the immune-dominant capsid protein
and contains the most important neutralization epitopes. It
shows a sequence divergence and has been used for mo-
lecular type assignment and evolutionary study. On the
basis of the molecular characterization of VP1, EV71 can
be phylogenetically classified into three genotypes (A, B,
and C). Genotypes B and C can be further divided into sub-
genotypes B1-B5 and C1-C4, respectively. Genotypes B and
C are distributed worldwide and exhibit distinct evolution-
ary characteristics, while genotype A is much less common
[18,19]. EV71 is likely transmitted via oral-fecal route and is
possibly shed from the respiratory tract via aerosolized
droplets. EV71 is highly contagious and easily infects per-
sons in close contact with other infected individuals. The
incubation period for EV71 is assumed to be approximately
5 days (d) with the median duration of virus shedding
period estimated to be 2 d in close contact group, 18 d in
mild HFMD and 25 d for severe HFMD [20]. The median
basic reproductive number for EV71 is 5.48, which is ap-
proximately two-fold higher than that of coxsackievirus
(CV) type A16 infection (2.50 d) [21].
Since the late 1990s, EV71 infection has been docu-
mented in many Asian countries [11,22-28]. Therefore,
HFMD has been included in the communicable disease
reporting system of the Thai Ministry of Public Health
since 2001. Reports from the ministry revealed that the
number of sporadic HFMD cases in Thailand during
2007 to 2011 was approximately 12,000 to 18,000 cases
annually. However, a large-scale outbreak of HFMD was
first reported on July 19, 2012. This outbreak affected
more than 39,000 patients with an estimated incidence
of 62.7/100,000 person-years during the outbreak period
[29] and was the highest in a decade. By the end of July,
three subsequent deaths were reported. Of those, one
case was a girl aged > 2 years 8 months from Bangkok
who had a history of frequent asthma exacerbation. An-
other case involved a 2 years old boy from a Cambodian
migrant family who had been living in Rayong province.
Both had been diagnosed with HFMD with respiratory
failure and died soon after hospitalization, but withoutneurological complications. In addition, a 16 years old
boy in Sakaeo province had been diagnosed with HFMD
with brain encephalitis and succumbed to heart and re-
spiratory system failure. Laboratory tests on throat swab
specimens implicated EV71 subgenotype B5 (EV71-B5)
in all these fatal cases. Although the epidemiology and
seroepidemiology of EV71 and other enteroviruses have
been well-studied in many countries, limited surveillance
data are available in Thailand. In this study, we analyzed
the enteroviral etiology associated with HFMD and HA
in Thailand from 2008 to 2013 and aimed to identify
evidence that could explain the sudden outbreak of
HFMD and HA in 2012. We also assessed the Thai pop-
ulation’s immunity against EV71-B5 using archived sera
collected before the large outbreak in 2012. The know-
ledge gained will be useful in understanding the viral




The study protocols were approved by the institutional re-
view board of the Faculty of Medicine, Chulalongkorn Uni-
versity, Thailand. The epidemiological study was conducted
on clinical specimens collected upon conclusion of routine
examinations and stored as anonymous. Serum samples
were obtained from healthy individuals from two previous
studies (influenza and biliary atresia control group) [30,31].
Patient identifiers including personal information (name,
address) and hospitalization number were removed from
these samples to protect patient confidentiality. Since the
data obtained for this study were de-identified, written con-
sents were waived. Permission for specimen utilization had
been granted by the Director of King Chulalongkorn Me-
morial Hospital. The research protocols for prospective
molecular epidemiological and seroepidemiological studies
were approved under protocol numbers IRB390/55 and
IRB068/56, respectively, and conducted in compliance with
the principles of the Declaration of Helsinki.
Case definition and data collection
Case definitions for the diseases are as followed: patient
with HA was defined as having well-characterized vesicular
enanthem, oral ulcers on the anterior tonsil pillars, soft pal-
ate, buccal mucosa, or uvula. Patients were diagnosed with
HFMD if they had oral ulcers mainly on the buccal mucosa
and tongue, accompanied by typical vesicular rashes most
commonly on the extensor surfaces of the hands, feet,
knees, and/or buttock. A severe case was defined as having
HFMD or HA and accompanied by the occurrence of at
least one of the following complications: aseptic meningitis,
myocarditis, encephalitis, pulmonary oedema, haemor-
rhage, acute flaccid paralysis, and cardiopulmonary collapse
[11,32]. Additionally, patients could be classified as having
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vous system complication.
Clinical specimen and data collection
Clinical specimens were collected from patients who
met the inclusion criteria and information on patient
demographics (age, sex and hospital location), clinical
symptoms, discharge diagnosis and the date of sample
collection were recorded using a standardized form. All
specimens were then transported within 48 hours to the
Center of Excellence in Clinical Virology, Chulalongkorn
Hospital, for causative pathogen identification. During
the period from 2 June 2008 through 3 October 2013,
we received 1,239 clinical specimens obtained from
1,182 in- and outpatients who presented signs and
symptoms of HFMD or HA and were admitted to hospi-
tals and medical centers in several parts of Thailand.
Among these, 224 cases were collected from the
Pediatrics Department of Chulalongkorn Hospital in
Bangkok between 2008 and 2013. Additional 682 cases
were from 17 hospitals and medical centers located in
Bangkok. Another 276 cases were from collaborative
provincial tertiary hospitals in 5 different provinces in-
cluding 268 cases from KhonKaen (northeastern
Thailand), 4 cases from Saraburi (central Thailand), 2
cases from Chonburi (eastern Thailand), and 1 case each
from SuphanBuri (central Thailand) and Uttaradit
(northern Thailand) (Figure 1). All of the cases outside
of Chulalongkorn Hospital were received during the out-
break in 2012 and 2013. Types of clinical specimens are
as followed: of all 1,239 samples, 822 were rectal swabs,
196 were stool samples, 123 were throat swabs, 35 were
blood components (serum, EDTA and clotted blood), 18
were cerebrospinal fluids, 17 were vesicle fluids and
swabs, 14 were nasal swabs, 5 were nasopharyngeal suc-
tions, 3 were sputum samples, 2 were nasal washes, 3
were mouth ulcer tissues, and 1 was a saliva sample.
Enterovirus screening and molecular typing by
phylogenetic analysis
Total virus nucleic acid and molecular typing of enterovirus
from samples were previously described [33,34]. Briefly,
pan-enterovirus (pan-EV) primers were employed for en-
terovirus detection by amplifying a target site within the
highly conserved 5′-UTR using semi-nested polymerase
chain reaction (PCR). To further confirm the enterovirus
type, CODEHOP degenerate primers targeting the VP1
gene of all enterovirus types were used [35]. Different sets
of specific primers targeting the VP1 gene for all genotypes
and/or types of EV71, CV-A16, and the current disseminat-
ing CV-A6 viruses were employed [33]. The amplified
products were purified using the HiYield Gel DNA Frag-
ment Extraction kit (RBC Bioscience, Taiwan). All sequen-
cing was performed bi-directionally using the primers ofthe 2nd round PCR by an automated cycle DNA sequencer
(First BASE Laboratories, Malaysia).
The nucleotide sequences were edited using the Seq-
man program of DNASTAR Software (v5.0). Sequences
were subjected to BLAST analysis and aligned using the
multiple alignment program MAFFT (v7.0) (http://mafft.
cbrc.jp/alignment/server/index.html) followed by manual
editing with BioEdit program (v7.1.9) (http://www.mbio.
ncsu.edu/bioedit/bioedit.html). In order to classify en-
terovirus types, which were directly identified from the
clinical specimens, neighbor joining phylogenetic ana-
lysis was performed. The genetic distances were calcu-
lated according to the maximum composite likelihood
model with 1,000 bootstrap pseudo-replicates and pair-
wise deletion for missing data implemented in MEGA
software (v5.0) (http://www.megasoftware.net/). The nu-
cleotide sequences obtained from this study have been




The samples were cross-sectionally stored sera collected
between 2009 and July 2012 (prior to the outbreak) from
healthy individuals of different age groups who had par-
ticipated in previous serosurveillance studies, including
volunteers and medical personnel in Bangkok and Khon-
Kaen [30,31]. None of the participants presented any
symptoms of HFMD or HA at the time of serum collec-
tion. The stored data included age band, gender, locality
or medical centers, any recorded symptoms or clinical
information, referral source, the month of sample collec-
tion, and the results of other virology tests for each sam-
ple (when available). In order to determine the age-
related seroprevalence of EV71 neutralizing antibody
(NAb) against EV71-B5, 161 subjects were categorized
into six age groups (infants aged ≤ 6 months, children
aged > 6 months to 2 years, pre-elementary school chil-
dren aged > 2 years to 6 years, elementary school chil-
dren aged > 6 years to 12 years, adolescents aged > 12
years to 18 years, and adults aged > 18 years).
NAb detection by epitope-blocking ELISA assay
The NAb titer was measured by using rhabdomyosar-
coma (RD) cell based microneutralization-ELISA assay.
The virus strain used in this study was EV71-B5 desig-
nated EV71/Taiwan/1745/08 (FJ357352), which shared >
99% amino acid sequence to the previously defined Thai
strains based on both whole genome and VP1 sequence
analysis [36]. The diluted serum samples were mixed
with an equal volume of 200 tissue culture half-infective
dose of the virus, and then incubated at 37°C for 2 hours.
After the incubation period, the antibody-virus mixtures
were added to the microtiter plates containing 1.5 × 105
Figure 1 Geographic distribution of the study population during the HFMD outbreak in 2012 in Thailand. Closed circles on the map
indicate the locations and numbers of patients collected during the outbreak period (red). Data of the estimated numbers of cases per 100,000
person-year in different regions (if available) were obtained from the Thai Ministry of Public Health of Thailand and are indicated under the
geographic region (black).
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CO2 incubator at 37°C for 24 hours. The EV71 virus
antigen was detected by ELISA and the optical density
was read at a primary wavelength of 450 nm using a mi-
croplate reader. The standard NAb level, which reflects
defensive capacity against EV71, has not been assigned.
We therefore defined a cutoff value of 1:8 to be sero-
positive, similar to the previous serosurveillance studies
and preclinical evaluation of the candidate vaccine [37].
The highest dilution of serum samples that inhibited
virus growth and prevented the occurrence of cytopathiceffect was considered the neutralization antibody titer.
The cutoff values for data interpretation were 1:8-1:64,
1:128-1:256, and ≥ 1:512 (low-, medium-, and high-NAb
titers, respectively). Each serum specimen was tested in
duplicate to reduce assay variation.
Statistical analysis
Statistical data comparisons between various factors were
analyzed by means of Pearson χ2, unpaired T-test, or
Fisher’s exact test as appropriate using SPSS software
(v17.0) (Chicago, USA). All data were considered statistically
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titer (GMT) of positive sera and the corresponding 95%
confidence intervals (CI) were computed by taking the
log-transformation of the titer values, followed by antilog-
transformation.Results
Epidemiological data of study population
During the study period, a total of 1,239 clinical specimens
from 1,182 patients with confirmed or suspected diagnosis
of HFMD or HA were included. The number of monthly
cases for each year between 2008 and 2013 are shown in
Figure 2. While fewer than 40 cases were observed between
2008 and 2011, an outbreak occurred in 2012, which
peaked in July of that year. Since the specimens were sent
to our Center as anonymous samples, redundancy due to
multiple samplings or follow-up visits by the same individ-
uals could not be investigated. The majority of the cases
presented mild forms of HFMD or HA. A total of 67.3%
(795/1182) and 16.7% (197/1182) of all cases presented
with HFMD and HA, respectively, whereas 16.1% (190/
1182) had incomplete data on the clinical diagnosis
(Table 1). The remaining unspecified cases were categorized
as the HFMD/HA group. The average age of patients in
conjunction with the respective disease are also shown in
Table 1. Among the study population, 123 cases (10.4%) are
of unknown age (37 cases of HFMD, 5 cases of HA, and 81
cases of HFMD/HA). The overall age distribution of en-
rolled patients was between 1 d and 54 years old (y). The
mean age was 3.6 years ± 5.0 years and median age was 2.5
years. There were no statistical differences with regards to
male-to-female ratio among patients in the different disease
groups.Figure 2 The distribution of HFMD and HA cases for each month betw
and August in 2012.Genotype change of enteroviruses in Thailand during
2008 to 2013
Using the standard semi-nested pan-EV RT-PCR assay, we
identified enteroviruses in 59.7% (706/1,182) of all the cases
(Table 1). Phylogenetic analysis of VP1 sequences obtained
from this study along with others from the GenBank data-
base a total of 477 sequences examined showed that 9.1%
were positive for EV71 and 31.3% were various CV types
(Figure 3A). The latter was further categorized as EV-A
species, including 70.5% CV-A6 (260/369), 27.6% CV-A16
(102/369), 1.1% CV-A10 (4/369), and 0.8% CV-A5 (3/369)
with bootstrap values higher than 95% (Figures 3B-C).
Figure 4 shows the distribution of the predominant geno-
types detected throughout the study period. Both EV71 and
CV-A16 were predominant in HFMD cases compared to
HA cases (p < 0.05). Age distribution of the enterovirus in-
fected patients is shown in Figure 5A. HFMD patients in-
fected by CV-A16 (2.7 years ± 1.5 years with a median age
of 2.5 years) were generally younger than those infected by
EV71 (3.4 years ± 3.4 years with a median age of 2.6 years)
and the non-EV infected group (4.4 years ± 3 years with a
median age of 6.3 years). However, these differences were
not statistically significant. When we compared the correl-
ation between the clinical diagnosis and the different viral
infection, the result showed that patients with HFMD diag-
nosis had a higher rate of EV71 infection (61.1% (66/108))
compared to those with HA (1.9% (2/108)) and HFMD/HA
(37% (40/108)).
Between 2008 and 2011, a total of 139 sporadic and en-
demic cases of HFMD and HA in Bangkok were examined.
Most enteroviruses detected belonged to genotypes within
the enterovirus species A (60.4% (84/139)). EV71 was the
most prevalent among the endemic cases, while CV-A16
was not found. In 2008, EV71 and CV-A6 were detected ineen the years 2008 and 2013. An outbreak occurred between June
Table 1 Demographic and clinical data associated with different enterovirus genotypes
HFMD HA HFMD/HA All
No of case 795 (67.3%) 197 (16.7%) 190 (16.1%) 1182
No of sample 833 (67.3%) 202 (16.4%) 202 (16.4%) 1237
Age range (median) 4d to 54y (2.4y) 3 m to 16y (2.6y) 1 m to 50y (3y) 4d to 54y (2.5y)
Mean age ± SD 3.4y ± 4.8y 3.4y ± 3.0y 5.1y ± 8.3y 3.6y ± 5.0y
Sex ratio (F:M) 1:1.4 1:1.1 1:1.2 1:1.3
Virology: EV71 66 (8.3%) 2 (1%) 40 (21.1%) 108 (9.1%)
CV-A16 65 (8.2%) 2 (1%) 35 (18.4%) 102 (8.6%)
Other CV-A 217 (27.3%) 22 (11.2%) 28 (14.7%) 267 (22.6%)
Pan-EV 131 (16.5%) 88 (44.7%) 10 (5.3%) 229 (19.4%)
Negative 316 (39.7%) 83 (42.1%) 77 (40.5%) 476 (40.3%)
HFMD, Hand, foot, and mouth disease; HA, Herpangina; EV71, Human enterovirus 71; CV-A, Coxsackievirus species A; Pan-EV, Pan-enterovirus; y, year old;
m, month old.
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and phylogenetic analysis based on VP1 sequences of EV71
revealed the circulation of various genotypes of EV71 in-
cluding 6 strains of EV71-C4, 5 strains of EV71-C1, 2
strains of EV71-C2, and 1 strain of EV71-B5 (Figure 4). In
2009, 32% (10/31) and 23% (7/31) of cases showed EV71
and CV-A16 infection, respectively. The EV71 genotype C4
was the most prevalent (8/10), followed by genotype B5 (2/
10). Other enterovirus types were also detected including
one each of CV-A10 and CV-A6. In 2010, CV-A16 became
the predominant virus, constituting 48.9% (22/45) of all
cases. EV71 was detected only in 2 cases and both were B5
subgenotype. CV-A6 was sporadic with a total number of 4
cases (8.9%). In 2011, EV71 (29% (11/38)) predominantly
replaced CV-A16 (16% (6/38)), while EV71-B5 was the only
subgenotype identified suggesting a continuous circulation
of EV71-B5 in Thailand. Of these, 2 and 1 cases were diag-
nosed positive for CV-A10 and CV-A6, respectively.
During January to February 2012, only EV71 was iden-
tified among the study population (36.8% (7/19)). The
following month, this EV71 dissemination was replaced
by the infrequent CV-A6, which then circulated until
the end of the year. The number of cases sent to our
Center dramatically increased beginning in June 2012.
Of the 879 clinical specimens, CV-A6 was the predom-
inant virus and accounted for 28.4% of the cases (250),
followed by 6.9% CV-A16 (61), 0.5% for other minor en-
terovirus species A (4) and 22.4% for untypable pan-EV
(197). It is noteworthy that EV71 accounted for only
6.6% (58/879) even though it was predominant in the
previous years. Co-circulation between different EV71
genotypes was also observed. Among those, 96.5% of
EV71 belonged to subgenotype B5 (56/58), while only
3.5% (2/58) were subgenotype C4. Among confirmed pa-
tients, the average age during the large outbreak was 3.1
years ± 4.3 years with a median age of 2.3 years. These
data therefore suggest that HFMD and HA frequentlyoccurred in young children. Most of the cases presented
with mild HFMD symptoms (77.1% (678/879)), and mild
HA cases accounted for 18.8% (165/879). During the
outbreak, there were 6 mild HFMD patients who had
presented with distinct diseases including 3 cases with
acute febrile illness diagnosis and 1 case each with ab-
dominal pain, exudative tonsillitis, and upper respiratory
tract illness. Two severe HFMD with myocarditis and
complex febrile convulsion were observed. The median
age of all of these patients was 3.2 years. However, all
cases tested negative by both pan-EV and specific PCR
screening. Analysis of the clinical manifestations showed
that patients infected with CV-A6 had a higher rate of
skin vesicles and ulcers particularly in the perianal area,
knees and elbows than patients infected with EV71 and
CV-A16. However, no significant difference was found.
In 2013, EV71 and CV-A16 were detected in 9% (15/
164) and 7% (11/164), respectively. Although no large
scale outbreak occurred in 2013, these rates are similar
to those reported in the previous years. Among the
EV71 infection cases, B5 was the only subgenotype iden-
tified. As for the seasonal distribution of HFMD and HA
cases attributable to enteroviruses, it mainly occurred in
two annual periods (between June and October in 2008,
2011 and 2012 and between January and July in 2010).
Furthermore, HFMD and HA were found throughout
the year in 2013. The two annual epidemic peaks corres-
pond to the overall enterovirus circulation consistent
with previous years.
Seroprevalence against EV71-B5
The analysis of the NAb titers against EV71-B5 in six
age groups is shown in Figure 5B. The overall male-to-
female ratio was 1:1.27. The measured NAb levels were
as follows: 67.9% (72/106), 26.4% (28/106), and 5.7%
(6/106) corresponding to low, medium and high NAb
titer, respectively. Serology showed that of the six infants
Figure 3 Neighbor-joining estimates of the phylogenetic relationship for enteroviruses detected among Thai pediatric children during 2008-
2013. The trees were generated on the basis of partial VP1 nucleotide sequence data. Virus strains characterized in this study are indicated with colored
dot according to year of sample collection and with species as the followings: (A) EV71, (B) CV-A6 and CV-A10 and (C) CV-A16. Dash lines indicate subge-
notype of EV71 and vertical lines indicate subgenotypes of EV71 and types of CV-A. Scale bar indicates the number of nucleotide substitutions per site.
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Figure 4 Successive appearance and distribution of predominant types and genotypes of enterovirus between 2008 and 2013.
Numbers of cases are indicated after types and genotypes of viruses.
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(66.7%). The age-specific seroprevalence was 42.5% (17/
40) in children aged > 6 months to 2 years and remained
relatively low in preschool children aged > 2 years to 6
years at 48.3% (14/29). There was no statistically signifi-
cant difference in seropositive rates either in children
aged 6 months to 2 years or in children aged 2 years to
6 years (p = 0.008). However, there was a significant in-
crease in the mean seropositive rate (88.2%) in elemen-
tary school children aged > 6 years to 12 years compared
to preschool children (p = 0.001). Seropositive rate for
EV71 remained steady at approximately 78.8% (41/52) in
children > 12 years of age, indicating an increase among
older children and adults compared to younger children.
To analyze the immunity level, GMT for EV71 NAb was
tested. The overall GMT for EV71-B5 was 46.2 with 65.6
(95% CI). Although the sample number is low, our result
suggests that the NAb titer distribution pattern was sig-
nificantly lower in infants aged ≤ 6 months (GMT of
13.5). GMT appeared to be highest at 78.8 among chil-
dren aged 6 years to 12 years. The GMT distribution
was lower in children 12 years to 18 years (GMT of
38.1) similar to that observed in adults > 18 years (GMT
of 25.1). Although the study population is relatively
small and should be regarded as preliminary, this is
the first seroepidemiological characterization of EV71 in
Thailand.
Discussion
HFMD and HA outbreaks associated with EV71
infection continue to pose an enormous public healthproblem with increasing morbidity and mortality in the
Asian-Pacific region over the past decades. The prognos-
tic factor for pandemic spread is currently unknown.
Some studies have shown that EV71 dissemination cor-
relates with climate temperature and relative humidity
[38,39]. Currently, neither antiviral drugs nor approved
prophylactic vaccines against the predominant EV71 are
available. Candidate EV71 vaccines in Taiwan and China
are now in clinical trials [40-42]. Our study demon-
strated continuous inter- and intratypic shifts among the
EV71 outbreaks. Not only does the highly contagious
EV71 displays a rapid evolutionary change, but multiple
types of enterovirus such as CV-A16, CV-A6, CV-A10,
CV-B2, and echovirus 30 also have the potential to cause
epidemics [43-45]. This heterogeneity has hampered the
disease control and could prolong the persistence of dis-
eases in countries where multiple enterovirus strains co-
exist. It also highlights the necessity to develop an effect-
ive vaccine that elicits strong cross-neutralizing antibody
response against the different genotypes of enterovirus
and to establish an effective immunization protocol. Fur-
thermore, since Asian countries do not have a coordi-
nated enterovirus surveillance program, collaborative
international networks and proactive public health
policies are urgently needed. Targeted vaccination of the
population at risk especially based on the age-group and
incidence rate of EV71 infection described in this
study will be useful in the consideration for future
immunization strategy.
Epidemiological surveillances showed that outbreaks
of EV71 occurred cyclically every 2-3 years and virus
Figure 5 Distribution of types of enterovirus and serum NAb against EV71 subgenotype B5 in the study population. (A) Age
distribution of enterovirus infected patients with HFMD and HA during the study period and. Bar colors correspond to the numbers of patients
with different types of enterovirus identified during the study period are indicated in the graph. (B) Serum titer of NAb against EV71
subgenotype B5 relative to age. The seropositive rates of individuals with NAb titers of 2-fold dilution are plotted on the y-axis. The dash line
denotes the cumulative geometric mean titer according to donors’ age. The number of sera (161 total) from each of the six age groups are
indicated in the table below the graph.
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larly those younger than 3-5 years of age [46,47]. Previ-
ous serosurveillance studies have suggested that the
EV71 cyclical pattern is due to the proportion of herd
immunity among the susceptible children after a major
outbreak [48,49]. The first international report on EV71-
associated with HFMD in Thailand was documented in
2011 using stored clinical samples collected since 2008[34]. Another report utilized cell culture-based method
to identify the causative agent associated with an HFMD
outbreak in a hospital nursery unit [50]. Although this
method is generally reliable, it is labor-intensive, time-
consuming, and may fail to identify some types of virus.
Not surprisingly, only a small number of cases tested
positive. For these reasons, we used a highly sensitive
specific PCR technique for virus gene amplification in
Linsuwanon et al. Journal of Biomedical Science 2014, 21:16 Page 10 of 13
http://www.jbiomedsci.com/content/21/1/16order to genetically characterize the causative pathogens
and to estimate the virus activities associated with
HFMD and HA in Thailand from 2008 to 2013.
Considerable insights were gained into the evolution
and molecular epidemiology of circulating strains of en-
terovirus on the basis of the VP1 gene sequence analysis.
Published data on the enterovirus epidemiology revealed
that the shifts between EV71 genotypes B and C or be-
tween EV71 and other types of CV-A occurred simultan-
eously in Asian-Pacific countries [11,22-27]. In agreement
with previous findings, we demonstrated that a change
in the prevailing subgenotypes and types occurred over
time including the shift of EV71 to CV-A, which oc-
curred in 2010 (EV71 subgenotype C4 to CV-A16) and
2012 (EV71-B5 to CV-A6). Strains of EV71-B5 have
caused large outbreaks in Asian countries since 1997 in-
cluding epidemics in Malaysia, Brunei, Singapore, and
Taiwan. In addition, enteroviral infection appears to be
increasing in recent years, with the continual emergence
of the subgenotype C4 in China since 1998 [23,51-55].
In contrast, epidemiological studies in Europe, the
United States, and Australia have identified the circula-
tion of different subgenotypes including B1, B2, C1 and
C2 [56-61]. Our study also revealed that the reemer-
gence of EV71 subgenotype B5 occurred in Thailand
since 2010 and the virus strains identified during this
period were phylogenetically closer to viruses circulat-
ing in Malaysia, Singapore and Taiwan between 2008
and 2012. Therefore, international spread of emerging
genetic variants into new geographical areas seems to
be common and may contribute to large scale epi-
demics. Studies have shown that EV71-B5 strains iso-
lated from the large outbreak in Taiwan in 2008 are
related to those circulating in neighboring countries
[23,62,63]. Further correlation between the reemergence
of EV71 and transmission from neighboring countries
will require additional evolutionary and phylogeographic
studies.
We demonstrated that EV71 and CV-A16 are endemic
in Thailand since 2008. In mid-2012, Thailand experi-
enced the first large scale outbreak of HFMD and HA in
several parts of the country particularly in the central
(61.11 cases in 100,000) and the northern region (60.01
cases in 100,000). The initial outbreak began when the
number of suspected HFMD and HA cases sent to our
Center dramatically increased in June 2012. As a result,
we received about 25 times more samples than the pre-
vious year (879 cases in 2012 compared to 25-46 sam-
ples during 2008-2011). While samples positive for EV71
and CV-A16 were relatively low in most years, we dem-
onstrated that approximately 43% of enterovirus positive
cases were CV-A6 infections, highlighting the predomin-
ant role of CV-A6 in this outbreak. Interestingly, CV-A6
appeared sporadically since 2008 until it became themajor genotype in 2012. It is noteworthy that CV-A6
was associated with HFMD and HA outbreaks in Japan
[64,65], Finland [66,67], Singapore [53], Taiwan [68],
China [69,70], Spain [71,72], and France [73] between
2005 and 2012.
We investigated the seroprevalence of EV71 in the
Thai individuals using retrospective stored serum sam-
ples and the results showed high seropositive rates
against EV71-B5 in individuals aged > 6 years (82.3%
(71/86)). This suggests the presence of EV71 in Thailand
during or before the time of sample collection. Results
from epidemiological studies also revealed that EV71 in-
fection was largely found in young children < 6 years of
age, along with relatively low seropositive rates [74-76].
We found that the overall seropositive rate against
EV71-B5 decreased by approximately 10% in 2011 and
by 23% in 2012 compared to the rate in 2009 and 2010
(80%-84% seropositive rate). Therefore, the wide dissem-
ination of viruses could have resulted in herd immunity.
Our observation was also consistent with those of sero-
surveillance studies showing a similar seropositive pat-
tern prior to the large outbreaks in China and Taiwan
[77,78]. With respect to age, we further observed that in-
fants had a high seropositive rate early in life (≤
6 months; 66.7%), while more than 50% of children aged
> 6 months to 2 years had low NAb against EV71-B5, in-
dicating that NAb prevalence decreased with increasing
age and thereafter remained constant in the older age
groups. This rate was higher than the 50% observed in
children > 6 years in Taiwan prior to the large outbreak
in 2008 [78]. Furthermore, the age-specific GMT of
EV71-B5 in childhood appeared to increase with age and
was highest among primary school children aged > 6
years to 12 years, reflecting community-acquired virus
transmission in those age groups. Evidence from sero-
surveillance studies also showed that immunity to one
genotype is not cross-protective against another geno-
type [79]. Studies using series serum samples of parturi-
ent mothers and their healthy newborn infants indicated
that the high proportion of herd immunity among sus-
ceptible children could have resulted from maternally
transferred-NAb [74,80]. However, the passive maternal
immunity to EV71 seems to be short-lived with approxi-
mately 42 days half-life, gradually decreases around the
age of 4 months to 6 months and is undetectable at
12 months of age [74,81]. This could lead to the accu-
mulation of individuals susceptible to EV71 infection,
especially among older children, which may be respon-
sible for the nationwide large outbreaks in many coun-
tries including Thailand. Based on the results from the
cohort studies together with our results from Thai sub-
jects, we recommend vaccination during the first year of
life, particularly when infants are 6 months to 12 months
of age.
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enterovirus types and their pathogenicity. In a study from
the Netherlands, patients with EV1 genotype B infection
were more likely to have neurologic complications than
those infected with other genotypes [1]. However, studies
from Taiwan and Malaysia demonstrated that there were
no statistically significant differences in type variability be-
tween the different levels of clinical complication [11,82].
In this study, we found no significant differences in clinical
complications caused by CV-A6 or other subgenotypes of
EV71. We are aware that the prevalence of enteroviruses
identified in Thailand may be underestimated, possibly due
to the high proportion of underreported cases in children
since infections often produce mild symptoms, self-
limiting, and thus may not have received medical care.
To enhance the sensitivity of the current system in
Thailand, surveillance by both physicians and con-
firmed laboratory diagnosis is crucial to predict EV71
and other enterovirus outbreaks in the future. Hospital
and healthcare staff in both the public and private sec-
tors should either report unusual cases to the provin-
cial health bureau or ask for assistance from the health
ministry.
Conclusions
Large epidemics of HFMD have never been documented in
Thailand prior to 2012, yet the high seropositive rate of this
study population suggests that the causative pathogen
EV71 was already widely circulated in Thailand. Decreased
EV71 circulation in early 2012 and in previous years might
have increased the number of susceptible young children,
which eventually resulted in the large outbreak in 2012.
This is the first study to describe the seroepidemiology of
EV71 in Thailand. Further work to support the hypothesis
that natural EV71 transmission occurs largely among popu-
lations especially in preschool settings will require add-
itional comprehensive serosurveillance studies.
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